Pharmaceutical and Biopharmaceutical Companies to Dominate the Companion Diagnostics Market

Companion Diagnostics Market

Increasing demand for next-generation sequencing, the growing significance of companion diagnostics in drug development, and the rising number of clinical trials are the major factors driving the growth of this market.

Advantages of companion diagnostics, the growing need for targeted therapy, the rising importance of personalized medicine, the increasing global incidence of cancer, and the ever-increasing application areas of companion diagnostics are driving the growth of the global companion diagnostics industry.

Get More Information @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155571681

Extractables/leachables testing services segment is expected to dominate the companion diagnostics market in 2019. The large share of this segment can be attributed to the ease of use and widespread availability of PCR kits & reagents in companion diagnostic testing, growing applications of PCR in the high-throughput detection of mutants with a limited or low allele frequency of genes, and high turnaround time of PCR as compared to other technologies.

Pharmaceutical & biopharmaceutical companies are expected to account for the largest share of the companion diagnostics market in 2019. The large share of this segment can majorly be attributed to the extensive usage of companion diagnostics in these industries owing to their growing prominence in drug development and the increasing importance of companion diagnostic biomarkers. The increasing demand for personalized medicine as well as the high demand for targeted therapies for various diseases and disorders is also expected to drive the demand and uptake of companion diagnostics among pharmaceutical & biopharmaceutical companies.

Companion diagnostics market in the APAC is estimated to grow at the highest CAGR during the forecast period. The high incidence of cancer, increasing proteomics & genomics research, growing research funding, rising investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics in several APAC countries are expected to drive the growth of the APAC market.

Recent Developments

Amazon_Audible
  • In May 2019, QIAGEN N.V. launched the therascreen PIK3CA RGQ PCR Kit in PIQRAY (alpelisib) therapy in the US to enhance its product portfolio in the companion diagnostics market.
  • In April 2019, Myriad Genetics, Inc. (US) and AstraZeneca plc (UK) and Merck Group (Germany) entered into a partnership, to identify unmet medical needs in men related to metastatic castration-resistant prostate cancer and expand the company’s patient access in the market.
  •  In September 2017, Abbott Laboratories (US) acquired Alere Inc. (US). This company enhances its point of care diagnostics segment in fast-growing diagnostics channels, thus significantly advancing Abbott’s global diagnostics presence and leadership.
  • In September 2017, Abnova Corporation entered into third-party diagnostics by offering molecular diagnostics in precision medicine and liquid biopsy testing services in China. This will help the company to establish its position in the Chinese market.

Get More Information @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155571681

Leading Companies

Prominent players operating in the global companion diagnostics market are F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (US), QIAGEN N.V. (Germany), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina, Inc. (US), bioMérieux SA (France), Myriad Genetics, Inc., (US), Sysmex Corporation (Japan), Thermo Fisher Scientific Inc. (US), Abnova Corporation (Taiwan), and Guardant Health, Inc. (US).

I consult businesses as a Corporate Communicator where I help companies about the growth of the healthcare market and solve their companies growth and research challenges through my creative marketing strategies. Reach out to me in case you have something I can help with.

web hosting